JAIDS Journal of Acquired Immune Deficiency Syndromes Publish Ahead of Print
1 DOI: 10.1097/QAI.0000000000001561 2
PrEP Use During Periods of HIV Risk Among East African Women in Serodiscordant Relationships
3 4
Authors: Maria Pyra MPH1,2, Jessica E. Haberer MD MS7,8, Renee Heffron MPH PhD1,2, Lara Kidoguchi MPH2, Elizabeth R.
6
Brown MS ScD3,6, Elizabeth A. Bukusi MM MPS PhD2,4,9, Stephen Asiimwe MBcHB MPH10, Connie Celum MD MPH1,2,5, Elly
7
Katabira MD FRCP11, Nelly R. Mugo MBChB2,9, and Jared M. Baeten MD PhD1,2,5 for the Partners Demonstration Project
8
Team
9
EP TE
D
5
10
1
Department of Epidemiology, 2Department of Global Health, 3Department of Biostatistics, 4Department of Obstetrics
11
and Gynecology, 5Department of Medicine, University of Washington, Seattle USA; 6Vaccine and Infection Diseases and
12
Public Health Science Division, Fred Hutchinson Cancer Research Center, Seattle USA; 7Massachusetts General Hospital
13
Global Health and Harvard Medical School, Boston USA; 8Department of Medicine, Harvard Medical School, Boston USA;
14
9
15
Makerere University, Uganda
Kenya Medical Research Institute (KEMRI); 10Kabwohe Clinical Research Center, Uganda; 11Infectious Disease Institute,
C
16 Word count: 2004/2000
18
Running Title: PrEP Adherence in East African Women
19
C
17
*Corresponding author: Jared M. Baeten
21
University of Washington Department of Global Health
22
325 Ninth Avenue Box 359927
23
Seattle, WA 98104
24
Phone: +1-206-520-3808
25
Fax: +1-206-520-3831
26
Email: [email protected]
A
20
1
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
27 28
Data was presented at HIV Research for Prevention (HIV R4P) 2016, October 17-21, in Chicago, IL , USA.
29 Funding
31
The Partners Demonstration Project was funded by the National Institute of Mental Health of the US National Institutes
32
of Health (R01 MH095507), the Bill & Melinda Gates Foundation (OPP1056051), and the US Agency for International
33
Development (AID-OAA-A-12-00023). The contents are the responsibility of the authors and do not necessarily reflect
34
the views of USAID, NIH, or the United States Government.
35
The authors report no conflicts of interest related to this work.
EP TE
D
30
36 37
Abstract (255/250):
38
Background: PrEP is efficacious for African women at risk for HIV, but data on adherence outside of clinical trials are
39
sparse. We describe the persistence and execution of PrEP use among women participating in a large open-label PrEP
40
demonstration project, particularly during periods of HIV risk.
41
Setting & Methods: 310 HIV-uninfected women in HIV serodiscordant couples in Kenya and Uganda were offered and
43
accepted PrEP. Electronic monitoring caps were used to measure daily PrEP adherence. Time on PrEP while at risk for
44
HIV (when the HIV-infected partner was on ART
1 DOI: 10.1097/QAI.0000000000001561 2
PrEP Use During Periods of HIV Risk Among East African Women in Serodiscordant Relationships
3 4
Authors: Maria Pyra MPH1,2, Jessica E. Haberer MD MS7,8, Renee Heffron MPH PhD1,2, Lara Kidoguchi MPH2, Elizabeth R.
6
Brown MS ScD3,6, Elizabeth A. Bukusi MM MPS PhD2,4,9, Stephen Asiimwe MBcHB MPH10, Connie Celum MD MPH1,2,5, Elly
7
Katabira MD FRCP11, Nelly R. Mugo MBChB2,9, and Jared M. Baeten MD PhD1,2,5 for the Partners Demonstration Project
8
Team
9
EP TE
D
5
10
1
Department of Epidemiology, 2Department of Global Health, 3Department of Biostatistics, 4Department of Obstetrics
11
and Gynecology, 5Department of Medicine, University of Washington, Seattle USA; 6Vaccine and Infection Diseases and
12
Public Health Science Division, Fred Hutchinson Cancer Research Center, Seattle USA; 7Massachusetts General Hospital
13
Global Health and Harvard Medical School, Boston USA; 8Department of Medicine, Harvard Medical School, Boston USA;
14
9
15
Makerere University, Uganda
Kenya Medical Research Institute (KEMRI); 10Kabwohe Clinical Research Center, Uganda; 11Infectious Disease Institute,
C
16 Word count: 2004/2000
18
Running Title: PrEP Adherence in East African Women
19
C
17
*Corresponding author: Jared M. Baeten
21
University of Washington Department of Global Health
22
325 Ninth Avenue Box 359927
23
Seattle, WA 98104
24
Phone: +1-206-520-3808
25
Fax: +1-206-520-3831
26
Email: [email protected]
A
20
1
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
27 28
Data was presented at HIV Research for Prevention (HIV R4P) 2016, October 17-21, in Chicago, IL , USA.
29 Funding
31
The Partners Demonstration Project was funded by the National Institute of Mental Health of the US National Institutes
32
of Health (R01 MH095507), the Bill & Melinda Gates Foundation (OPP1056051), and the US Agency for International
33
Development (AID-OAA-A-12-00023). The contents are the responsibility of the authors and do not necessarily reflect
34
the views of USAID, NIH, or the United States Government.
35
The authors report no conflicts of interest related to this work.
EP TE
D
30
36 37
Abstract (255/250):
38
Background: PrEP is efficacious for African women at risk for HIV, but data on adherence outside of clinical trials are
39
sparse. We describe the persistence and execution of PrEP use among women participating in a large open-label PrEP
40
demonstration project, particularly during periods of HIV risk.
41
Setting & Methods: 310 HIV-uninfected women in HIV serodiscordant couples in Kenya and Uganda were offered and
43
accepted PrEP. Electronic monitoring caps were used to measure daily PrEP adherence. Time on PrEP while at risk for
44
HIV (when the HIV-infected partner was on ART
